Monthly pegloticase vs placebo
Quality of life ‐ not reported · participants with tophi in gout
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).
Monthly pegloticase showed no clear difference in total adverse events compared with placebo (moderate certainty).
Monthly pegloticase showed no clear difference in proportion with complete resolution of tophi compared with placebo (moderate certainty).
The review found no eligible studies for this question.